Shield Therapeutics PLC on Wednesday said it is on track to turn free cash flow positive by the end of the year, as the pharmaceutical company reported a sharp rise in second quarter revenue.
Shares in the company jumped 16% to 4.11 pence each in London on Wednesday morning.
Shield Therapeutics, which has a focus on iron deficiency, said revenue in the second quarter of 2025 surged 86% on-year to $12.8 million from $6.9 million. It doubled on-quarter from $6.4 million.
Total prescriptions of its Accrufer iron deficiency drug surged to 47,000 from 36,800 in the first quarter. The average net selling price rose on-quarter to $231 from $187.
‘The company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025,’ Shield added.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
